Prosecution Insights
Prosecution Insights
40 pending office actions • 5 art units • 23 examiners • 0 of 40 (0%) have an AI response strategy ready • 26 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (8%) |
| §103 only | 9 (22%) |
| §112 only | 4 (10%) |
| Double-patenting only | 2 (5%) |
| Double-patenting + other | 7 (18%) |
| Multi-statute (no §101) | 15 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUDSON, AMY ROSE | 5 | 75.0% | +11.4% |
| POLIAKOVA-GEORGAN, EKATERINA | 4 | 64.0% | +17.9% |
| SULLIVAN, STEPHANIE LAUREN | 3 | 58.6% | +39.6% |
| GIBBS, TERRA C | 3 | 63.9% | +10.4% |
| TRAN, CHRISTINA L | 3 | 48.2% | +45.5% |
| WHITEMAN, BRIAN A | 2 | 68.4% | +16.7% |
| ALLEN, SARAH ELIZABETH | 2 | 60.9% | +45.0% |
| SHIN, DANA H | 2 | 27.0% | +27.4% |
| MCKILLOP, JOHN CHARLES | 2 | 56.3% | +40.7% |
| ZAHORIK, AMANDA MARY | 1 | 57.5% | +48.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18301089 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | CHONG, KIMBERLY | 127d overdue |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 85d overdue |
| 17736251 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | VANHORN, ABIGAIL LOUISE | 43d overdue |
| 18247314 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | GIBBS, TERRA C | 16d overdue |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | POLIAKOVA-GEORGAN, EKATERINA | 14d |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | PERSONS, JENNA L | 30d |
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 49d |
| 18259887 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | BRETZ, COREY LANE | 69d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 110d overdue |
| 18382562 | METHODS OF TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | POLIAKOVA-GEORGAN, EKATERINA | 51d overdue |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 38d overdue |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 32d overdue |
| 18247314 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | GIBBS, TERRA C | 16d overdue |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 4d overdue |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | POLIAKOVA-GEORGAN, EKATERINA | 14d |
| 18077271 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | GIBBS, TERRA C | 27d |
| Art Unit | Apps |
|---|---|
| 1637 | 14 |
| 1636 | 10 |
| 1635 | 9 |
| 1653 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18978602 | SNCA-TARGETING SIRNA COMPOSITIONS FOR TREATING SNCA-ASSOCIATED DISEASE | SULLIVAN, STEPHANIE LAUREN | 1635 | §103Other | Non-Final OA | 33d | Pending | Dec 12, 2024 |
| 18761504 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE | ZAHORIK, AMANDA MARY | — | §102§103§112 | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18613537 | 3'-OH RNA-CONTAINING OLIGONUCLEOTIDE DEPROTECTION | CHO, DAVID H | — | §102§103§112DP | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18434928 | COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | HUDSON, AMY ROSE | 1636 | §103 | Final Rejection | — | Pending | Feb 07, 2024 |
| 18577948 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | LEE, HOI YAN NMN | — | §102§103§112Other | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18403862 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING OR AT RISK OF DEVELOPING A NON-PRIMARY HYPEROXALURIA DISEASE OR DISORDER | WHITEMAN, BRIAN A | — | §102§103§112DP | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18542950 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | GIBBS, TERRA C | — | §103§112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18382562 | METHODS OF TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103Other | Non-Final OA | 51d overdue | Pending | Oct 23, 2023 |
| 18556180 | REDIRECTING RISC FOR RNA EDITING | ALLEN, SARAH ELIZABETH | 1653 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | DP | Non-Final OA | 38d overdue | Pending | Oct 03, 2023 |
| 18373397 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103 | Non-Final OA | — | Pending | Sep 27, 2023 |
| 18548634 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18236437 | PRION PROTEIN (PRNP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | YU, DELPHINUS DOU YI | 1636 | §103DP | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18547102 | FOLLICULIN iRNA COMPOSITIONS AND METHODS THEREOF | KONOPKA, CATHERINE ANNE | 1636 | §101§102§103§112DP | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18259887 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | BRETZ, COREY LANE | 1635 | §102§103 | Non-Final OA | 69d | Pending | Jun 29, 2023 |
| 18136386 | MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103§112Other | Final Rejection | 14d | Pending | Apr 19, 2023 |
| 18301089 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | CHONG, KIMBERLY | 1636 | §102§103Other | Final Rejection | 127d overdue | Pending | Apr 14, 2023 |
| 18131892 | SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES | ANGELL, JON E | 1637 | §102§103 | Non-Final OA | — | Pending | Apr 07, 2023 |
| 18247314 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | GIBBS, TERRA C | 1635 | §101§102§103§112 | Non-Final OA | 16d overdue | Pending | Mar 30, 2023 |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 1637 | §103§112 | Final Rejection | 85d overdue | Pending | Feb 09, 2023 |
| 18007007 | ATXN2 IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING ATXN2-ASSOCIATED NEURODEGENERATIVE DISEASES | WHITEMAN, BRIAN A | 1636 | §112 | Final Rejection | — | Pending | Jan 26, 2023 |
| 18015202 | Circular siRNAs | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | — | Pending | Jan 09, 2023 |
| 18001813 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | §102§103 | Final Rejection | — | Pending | Dec 14, 2022 |
| 18077271 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | GIBBS, TERRA C | 1635 | §112Other | Non-Final OA | 27d | Pending | Dec 08, 2022 |
| 18001065 | SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION | SHIN, DANA H | 1635 | §112 | Final Rejection | — | Pending | Dec 07, 2022 |
| 18001050 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103 | Non-Final OA | — | Pending | Dec 07, 2022 |
| 17999320 | COMPOSITIONS AND METHODS FOR INHIBITING MARC1 GENE EXPRESSION | SHIN, DANA H | 1635 | §112 | Non-Final OA | — | Pending | Nov 18, 2022 |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | 4d overdue | Pending | Oct 27, 2022 |
| 17995568 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | — | Pending | Oct 05, 2022 |
| 17937256 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | MCKILLOP, JOHN CHARLES | 1637 | §102§103§112DPOther | Non-Final OA | — | Pending | Sep 30, 2022 |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | §103 | Final Rejection | 32d overdue | Pending | Sep 29, 2022 |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | PERSONS, JENNA L | 1637 | §103§112 | Non-Final OA | 30d | Pending | Aug 24, 2022 |
| 17779706 | SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDES | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 26d overdue | Pending | May 25, 2022 |
| 17743498 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | DPOther | Non-Final OA | — | Pending | May 13, 2022 |
| 17736251 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | VANHORN, ABIGAIL LOUISE | 1636 | §103§112Other | Non-Final OA | 43d overdue | Pending | May 04, 2022 |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | DP | Final Rejection | 110d overdue | Pending | Mar 01, 2022 |
| 17668413 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALLEN, SARAH ELIZABETH | 1637 | §102§103 | Final Rejection | — | Pending | Feb 10, 2022 |
| 17619633 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | MCKILLOP, JOHN CHARLES | 1637 | §112DP | Final Rejection | — | Pending | Dec 16, 2021 |
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 1637 | §103§112Other | Final Rejection | 49d | Pending | Nov 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial